KURA shares rise on positive kidney cancer trial results

Kura Oncology (KURA) reported positive data from a kidney cancer clinical trial, which caused a jump in its shares. The specific percentage increase in share price was not disclosed, but the reported trial data suggests a favorable outcome for the company’s drug candidate. This positive news is likely to have implications for investor sentiment and trading volume as market participants assess the potential for future revenue. The market's response showcases the impact of clinical trial results on biotech stock performance.